Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1352364 | 0.97 | KDM4E (0.55) | KDM4ELMNACYP2C19TSHRNPSR1 | |
| SCHEMBL9471261 | 0.97 | KDM4E (0.55) | KDM4ELMNACYP2C19TSHRNPSR1 | |
| SCHEMBL11083062 | 0.94 | KDM4E (0.52) | KDM4ELMNACYP2C19TSHRNPSR1 | |
| Hydrochloric Acid SCHEMBL10768658 | 0.94 | KDM4E (0.52) | KDM4ELMNACYP2C19TSHRNPSR1 | |
| SCHEMBL20206752 | 0.78 | CRBN (0.48) | KDM4ELMNACYP2C19TSHRNPSR1 | |
| SCHEMBL15250760 | 0.73 | KDM4E (0.50) | KDM4ELMNACYP2C19TSHRNPSR1 | |
| SCHEMBL248285 | 0.71 | — | — | |
| SCHEMBL2324941 | 0.69 | — | — | |
| SCHEMBL2691041 | 0.69 | — | — | |
| SCHEMBL24372750 | 0.69 | CRBN (0.50) | KDM4ELMNACYP2C19TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001930-B1 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LAB (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | DAVIDSEN STEVEN K (US) | 2002-01-17 | — | — | US | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
| US-6235786-B1 | RHEUMATIC DISORDERS; BONE DISORDERS; ORAL DISEASES; ANTIULCER AGENTS; ANTITUMOR AGENTS | ABBOTT LABORATORIES | 2001-05-22 | — | — | US | disclosed |
| CN-1044474-C | Improved, large-scale process for azapirone synthesis | BRISTOL MYERS SQUIBB CO (US) | 1999-08-04 | — | — | CN | disclosed |
| CN-1115317-A | Improved, large-scale process for azapirone synthesis | BRISTOL MYERS SQUIBB CO (US) | 1996-01-24 | — | — | CN | disclosed |
| EP-0680961-A1 | Improved, large-scale process for azapirone synthesis | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | MMP1, MMP9, MMP3 | KDM4E 1586/4885LMNA 1058/4885CYP2C19 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.